Oncology Views & Analysis

Views & Analysis

Oncology

Oncology market dominance: As easy as ADC?

Antibody-drug conjugates are coming back to the fore, with talks of multi-billion dollar buyouts and a rapidly growing number of approvals.

Oncology

Diversity by design: the importance of DE&I in oncology tria...

“First, do no harm”; is an ethical axiom at the heart of medical research; physicians worldwide pledge to uphold the oath to serve patients.

Oncology

Phesi’s Dr Gen Li: New approaches to clinical trials in canc...

Dr Gen Li, founder and president of Phesi, a provider of AI-powered clinical development analytics, products and solutions, discusses some of the latest challenges facing the industry, incl

Oncology

Realising the promise of cancer vaccines

For years, the promise of therapeutic cancer vaccines has intrigued researchers working in the oncology space. And for good reason.

Oncology

Deep Dive: Oncology 2022

Eradicating cancer is an ambitious goal for oncologists and life science companies around the world.

Market Access

Are timely access and robust safety mutually exclusive?

The FDA approves new cancer treatments in half the time of the EMA – but does faster mean better? And how can regulators balance timely access with robust safety?

Oncology market dominance: As easy as ADC?

Diversity by design: the importance of DE&I in oncology tria...

Phesi’s Dr Gen Li: New approaches to clinical trials in canc...

Realising the promise of cancer vaccines

Deep Dive: Oncology 2022

Are timely access and robust safety mutually exclusive?

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Views & Analysis

Editor's Picks